Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis



Sloan, Derek J, Mwandumba, Henry C, Garton, Natalie J, Khoo, Saye H, Butterworth, Anthony E, Allain, Theresa J, Heyderman, Robert S, Corbett, Elizabeth L, Barer, Mike R and Davies, Geraint R ORCID: 0000-0002-3819-490X
(2015) Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases, 61 (1). 1 - 8.

This is the latest version of this item.

[img] Text
Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis.pdf - OA Published Version
Available under License : See the attached licence file.

Download (317kB)
[img] Text
civ195.pdf - Unspecified
Available under License : See the attached licence file.

Download (317kB)

Abstract

Background Antibiotic-tolerant bacterial persistence prevents treatment shortening in drug-susceptible tuberculosis, and accumulation of intracellular lipid bodies has been proposed to identify a persister phenotype of Mycobacterium tuberculosis cells. In Malawi, we modeled bacillary elimination rates (BERs) from sputum cultures and calculated the percentage of lipid body–positive acid-fast bacilli (%LB + AFB) on sputum smears. We assessed whether these putative measurements of persistence predict unfavorable outcomes (treatment failure/relapse). Methods  Adults with pulmonary tuberculosis received standard 6-month therapy. Sputum samples were collected during the first 8 weeks for serial sputum colony counting (SSCC) on agar and time-to positivity (TTP) measurement in mycobacterial growth indicator tubes. BERs were extracted from nonlinear and linear mixed-effects models, respectively, fitted to these datasets. The %LB + AFB counts were assessed by fluorescence microscopy. Patients were followed until 1 year posttreatment. Individual BERs and %LB + AFB counts were related to final outcomes. Results  One hundred and thirty-three patients (56% HIV coinfected) participated, and 15 unfavorable outcomes were reported. These were inversely associated with faster sterilization phase bacillary elimination from the SSCC model (odds ratio [OR], 0.39; 95% confidence interval [CI], .22–.70) and a faster BER from the TTP model (OR, 0.71; 95% CI, .55–.94). Higher %LB + AFB counts on day 21–28 were recorded in patients who suffered unfavorable final outcomes compared with those who achieved stable cure (P = .008). Conclusions  Modeling BERs predicts final outcome, and high %LB + AFB counts 3–4 weeks into therapy may identify a persister bacterial phenotype. These methods deserve further evaluation as surrogate endpoints for clinical trials.

Item Type: Article
Additional Information: Derek J. Sloan, Henry C. Mwandumba, Natalie J. Garton, Saye H. Khoo, Anthony E. Butterworth, Theresa J. Allain, Robert S. Heyderman, Elizabeth L. Corbett, Mike R. Barer, and Geraint R. Davies Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis Clin Infect Dis. (2015) 61 (1): 1-8 first published online March 16, 2015 doi:10.1093/cid/civ195
Uncontrolled Keywords: tuberculosis, sterilizing activity, persistence, lipid bodies, clinical trials
Depositing User: Symplectic Admin
Date Deposited: 21 May 2020 09:03
Last Modified: 12 Aug 2022 04:11
DOI: 10.1093/cid/civ195
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3086532

Available Versions of this Item